Articles
Tech Transfer of a Biologic Upstream Process
This insightful article delves into the intricacies of transferring technology in the biopharmaceutical industry. It highlights the importance of a structured and modular approach to ensure flexibility, consistency, and agility in meeting market needs.
Unlock the Secrets to Successful Biopharmaceutical Tech Transfer
In the rapidly evolving world of biopharmaceuticals, the ability to efficiently transfer manufacturing processes is crucial for meeting clinical and commercial demands. This article delves into the essential aspects of downstream processing, providing you with valuable insights and practical strategies to navigate the complexities of tech transfer.
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets.
Early-stage biotech: The wrong outsourcing strategy costs more than time
For early-stage biotech companies, innovation is just the beginning—the greater challenge lies in navigating the complex development path with limited time, resources, and visibility.
5 Ways Modern MES Solutions for Pharmaceutical Manufacturing
The source highlights the importance of adopting a modern Manufacturing Execution System (MES) in the pharmaceutical industry.
From Discovery to Delivery: The Rise of New Modalities
In the rapidly evolving landscape of pharmaceuticals and biotechnology, the emergence of multimodal drug discovery heralds a transformative era, where innovation and strategic foresight are paramount. This evolution is not a scientific leap, but also a technological one, fundamentally reshaping the competitive environment.
The New RNA World: Evolving RNA from Messenger to Versatile Therapeutic
RNA has evolved from a molecular messenger into a powerful and versatile therapeutic tool.
From Clinical to Commercial: Streamlining Cold Chain Logistics for Advanced Therapies
Cell and gene therapy (CGT) products require ultra-cold temperatures throughout manufacturing and distribution, posing significant challenges when transitioning from clinical development to commercialization.
Breaking the toxicology bottleneck for IND submissions
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, as Alejandro Fernandez Martell and James Berrie explain in this article originally published in Drug Target Review.
Accelerating the path to clinical filing applications with rapid toxicology material delivery
The application for investigational new drug (IND) and Clinical Trial Application (CTA) is a key step in initiating clinical trials/first-in-human (FIH) trials for a drug candidate.
